APPLICATIONS
One capability, applied across diagnostics and pharma
Codon-context attribution is a general measurement layer. The same methods support clinical decision-making, longitudinal monitoring, companion diagnostics and population-scale profiling.
PRIMARY
Immunotherapy response prediction
Guides USD 100,000–200,000+ per-patient treatment decisions by identifying who is unlikely to benefit, the question oncologists most need answered.
MONITORING
Recurrence & progression
Minimal-residual-disease and longitudinal deaminase-signature tracking to flag progression and resistance ahead of clinical manifestation.
PHARMA
Companion diagnostics & R&D
Patient stratification, trial enrichment, and companion diagnostics for the emerging class of deaminase-modulating therapeutics.
POPULATION
Multi-cancer & at-risk profiling
Germline deaminase genotyping and pan-cancer signature screening for earlier identification of risk.
A NEW THERAPEUTIC CATEGORY
Deaminase modulation is becoming a drug class.
In November 2025, GMDx founder Dr Robyn A. Lindley defined deaminase modulation as an emerging therapeutic class in the peer-reviewed literature, spanning oncology, autoimmune, neurological and genetic disease. As programmes in this class advance across the industry, each one needs to stratify patients by deaminase signature, the measurement layer GMDx provides.
$136B
Global cancer immunotherapy market, 2025; projected above $250B by 2030
$7.8B
Companion diagnostics market, 2025; projected $15.6B by 2030
Market figures are external industry estimates, provided as context.
ONCOLOGY
Our Immune Fitness Profile (IFP) is the most accurate genomic test developed so far to predict how patients will respond to cancer
The GMDx IFP Outperforms TMB and PD-L1 Tests
GMDx (2023)
GMDx - Tempus Real World Data (Exome, 20k genes)
GMDx (2024)
GMDx - Tempus Real World Data (Panel, 648 genes)
TMB
Shim et al. (2020)
PD-L1
Shim et al. (2020)
